Clinical Trials Browser

Phase 2 × Interventional × Brentuximab Vedotin × Clear all

NCT05922904 2026-04-15

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease

NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Phase 2 Recruiting

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Phase 2 Completed

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03755804 2026-02-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2 Active not recruiting

Hodgkin Disease, Neoplasms

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2 Completed

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Phase 2 Active not recruiting

DermatologicLymphoid

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT05357794 2026-01-12

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Phase 2 Recruiting

Mycosis Fungoides

NCT01920932 2025-12-03

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2 Active not recruiting

77 enrolled 20 charts

Hodgkin Disease, Neoplasms

NCT02588651 2025-11-21

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Phase 2 Completed

23 enrolled 15 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03113500 2025-11-14

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Phase 2 Active not recruiting

48 enrolled 8 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT03007030 2025-11-10

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Phase 2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07002216 2025-11-03

BrECADD

Phase 2 Recruiting

Hodgkin Disease

NCT01508312 2025-10-21

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

66 enrolled 14 charts

Hodgkin Disease

NCT07013565 2025-10-21

ACCELERATE

Phase 2 Active not recruiting

Lymphoma, Large-Cell, Anaplastic

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Hodgkin Disease

NCT02734771 2025-08-12

BV mini CHP

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Phase 2 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT05673785 2025-07-14

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Phase 2 Active not recruiting

Lymphoma

NCT01703949 2025-06-11

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03057795 2025-05-07

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Phase 2 Active not recruiting

62 enrolled 8 charts

Hodgkin Disease

NCT04587687 2025-04-24

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT02744612 2025-03-26

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

39 enrolled 9 charts

Hodgkin Disease

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02927769 2025-02-10

CheckMate 744

Phase 2 Completed

72 enrolled 24 charts

Hodgkin Disease

NCT03264131 2025-02-10

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Phase 2 Active not recruiting

16 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03712202 2024-11-06

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Phase 2 Active not recruiting

Hodgkin Disease

NCT02388490 2024-09-23

Bretuximab

Phase 2 Completed

25 enrolled 12 charts

Lymphoma, Recurrence

NCT02191930 2024-08-23

BVB

Phase 2 Completed

Hodgkin Disease

NCT03217643 2024-06-20

EATL-001

Phase 2 Completed

Enteropathy-Associated T-Cell Lymphoma

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

131 enrolled 28 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT01979536 2024-04-30

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Phase 2 Completed

137 enrolled 13 charts

Lymphoma, Large-Cell, Anaplastic

NCT04378647 2024-02-26

BRESELIBET

Phase 2 Recruiting

Hodgkin Disease

NCT06201507 2024-01-12

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT02398240 2023-10-26

Brentuximab for Newly Diagnosed Hodgkin Disease

Phase 2 Completed

Hodgkin Disease

NCT03947255 2023-10-13

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Phase 2 Terminated

12 enrolled 17 charts

Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Phase 2 Withdrawn

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT04334174 2023-02-03

BRENTICON-T

Phase 2 Withdrawn

Lymphoma, T-Cell

NCT02292979 2022-08-19

BREACH

Phase 2 Completed

Hodgkin Disease

NCT04138875 2022-06-23

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Phase 2 Withdrawn

Other hematologic neoplasm

Infectious Mononucleosis, Hematologic Neoplasms

NCT05006664 2021-09-01

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Phase 2 Unknown

Lymphoma, T-Cell, Peripheral

NCT02298283 2021-07-26

BRAPP2

Phase 2 Completed

Hodgkin Disease

NCT02499627 2021-05-27

FIL-BBV

Phase 2 Terminated

Lymphatic Diseases, Lymphoma

NCT02939014 2021-02-24

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Phase 2 Completed

39 enrolled 26 charts

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT02227433 2020-12-22

FIL_BVHD01

Phase 2 Completed

Hodgkin Disease

NCT02988843 2020-12-10

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Phase 2 Terminated

1 enrolled 8 charts

Neoplasms, Germ Cell and Embryonal

NCT02505269 2020-08-24

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Phase 2 Completed

34 enrolled 7 charts

Hodgkin Disease

NCT03474133 2020-07-21

BASALT

Phase 2 Unknown

Hodgkin Disease, Recurrence